Symbols

THRX(Delisted)

Theseus·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About THRX

Theseus Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company focused on transformative targeted therapies working to outsmart cancer resistance

Industry

Established Date

Listing Date

10/07/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.theseusrx.com

Security Type

Common stock

Office address

245 Main Street, Cambridge, Massachusetts 02142

Business

Introduction

Theseus Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware in December 2017. The company is a biopharmaceutical company dedicated to improving the lives of cancer patients by discovering, developing and commercializing transformative targeted therapies. The company's development program is aimed at addressing drug-resistant mutations that are key drivers of oncogenes, which are mutant genes that cause cancer. The company's goal is to develop "pan-variant" kinase inhibitors — inhibitors of all major carcinogenic and drug-resistant mutations in clinically important protein kinases.

Company Financials

EPS

THRX has released its 2023 Q3 earnings. EPS was reported at -0.31, versus the expected -0.36, beating expectations. The chart below visualizes how THRX has performed over recent quarters, highlighting trends in earnings surprises.